Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark Pharmaceuticals Ltd.

www.glenmarkpharma.com

Latest From Glenmark Pharmaceuticals Ltd.

Amid US Challenges, Will Glenmark’s R&D Pipeline Deliver?

Glenmark reported subdued Q2 earnings, with the management predicting that the US business environment could stay challenging for at least two years. The firm, though, was upbeat on the potential of certain R&D assets, with a monoclonal antibody seen as “most promising” from an out-licensing perspective and a combination for seasonal allergic rhinitis set for a US NDA filing early next year.

Sales & Earnings India

Competition Piles Up: 100 Teneligliptin Brands Now In India

A hundred teneligliptin brands (including the combination) are said to now jostle for space in the competitive Indian DPP-4 (dipeptidyl peptidase-4) inhibitor market. An uptick in volumes and a significant decline in the prices of teneligliptin probably mean that Merck’s Januvia and Novartis’ Galvus will need to keep a sharp eye on the molecule in the diabetes segment in India.

India Commercial

Otezla Versions On Horizon In India But Celgene Cool?

Several Indian firms appear to be gearing for the launch of generic versions of apremilast, with innovator Celgene seemingly undisturbed with the goings on, at least for now.

Market Intelligence India

Pipeline Watch: Phase II Readouts With SPK-8011, Velusetrag, GBR-830

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register